Q&A: Subretinal chip sheds light on blindness

Article

After peaking our interest earlier in the year we, at OTEurope, caught up with Professor Eberhart Zrenner, co-inventor of the subretinal alectronic chip from Retina Implant and coordinating investigator of the ongoing clinical study, to find out more and to learn about the paper published on this fascinating technology

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Related Content
Health Canada approves aflibercept biosimilar Aflivu

Health Canada approves aflibercept biosimilar Aflivu

Sydney M Crago
July 10th 2025
Article

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A close up of an eye with a brown iris, concept image for diabetic retinopathy and glaucoma research. Image credit: ©Made in Uruguay from Pexels – Canva.com

Perfuse Therapeutics shares findings from glaucoma and diabetic retinopathy trials of PER-001

Sydney M Crago
July 9th 2025
Article

Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Nationwide free transport for cataract patients through SpaMedica

Nationwide free transport for cataract patients through SpaMedica

Lynda Charters
July 8th 2025
Article

SpaMedica to offer free transport for all NHS cataract patients, supporting community care and reducing health inequalities.

A man in a bed takes a pill. Concept image for oral therapy, danegaptide non proliferative diabetic retinopathy medication. Image credit: ©Jelena – stock.adobe.com

Breye Therapeutics completes phase 1B trial of danegaptide oral therapy for diabetic retinopathy

Lynda Charters
July 8th 2025
Article

Investigators reported the oral therapy was well-tolerated in trials for early treatment of non-proliferative diabetic retinopathy and associated oedema

© 2025 MJH Life Sciences

All rights reserved.